European Innov­a­tion Coun­cil selects ISAR Bioscience pro­ject for break­through tech­no­logy in receptor research

The European Innov­a­tion Coun­cil (EIC) has announced the selec­tion of pro­pos­als from the 2023 EIC Pathfinder Open call, which funds ideas for new break­through tech­no­lo­gies. The Uni­S­ens con­sor­tium, organ­ized by ISAR Bioscience, is among the 53 pro­jects from all over Europe and from a wide range of fields - health, arti­fi­cial intel­li­gence, com­put­ing, envir­on­ment and energy. Our applic­a­tion was selec­ted from among 783 sub­mis­sions and is one of the few led by a small or medium-sized enter­prise (SME).

The Uni­S­ens con­sor­tium includes aca­demic and SME part­ners from the Czech Repub­lic, France, the Neth­er­lands, Spain, Switzer­land and Ger­many. It aims to develop a com­pletely new tech­no­logy for the dis­cov­ery of drugs that act on recept­ors - the largest and most import­ant group of thera­peutic drugs. “I am thrilled that the eval­u­at­ors in Brus­sels recog­nized the enorm­ous poten­tial of our cut­ting-edge tech­no­logy inspired by our sci­entific dis­cov­er­ies,” said Dr. Martha Som­mer, head of the receptor team at ISAR Bioscience and coordin­ator of the Uni­S­ens con­sor­tium. “We will now enter into nego­ti­ations with the EU to final­ize our grant agree­ment,” adds Pro­fessor Martin Lohse, Chair­man of ISAR Bioscience. Fund­ing for the four-year pro­ject is expec­ted to be well over €3 million.